Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Apremilast (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Amgen; Celgene Corporation
- 13 Jul 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Jul 2012 Primary endpoint 'American-College-of-Rheumatology-20%-response-criteria' has not been met according to a Celgene media release.
- 12 Jul 2012 Interim results published in the Media Release.